GL
CLDI icon

Governors Lane’s Calidi Biotherapeutics CLDI Stock Holding History

Governors Lane’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-25
Closed -$9.47K – 60
2024
Q2 		$9.47K Sell
25
-24
-49% -$12.3K ﹤0.01% 52
2024
Q1 		$53.5K Hold
49
– – ﹤0.01% 57
2023
Q4 		$143K Buy
+49
New +$210K 0.01% 54
2022
Q3 		– Sell
-521
Closed -$9.94M – 173
2022
Q2 		$9.94M Hold
521
– – 0.8% 30
2022
Q1 		$9.89M Hold
521
– – 0.72% 34
2021
Q4 		$9.82M Buy
+521
New +$9.82M 0.6% 39

Other funds holding CLDI

CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
CI
CPR Investments Rochester, Michigan $130M AUM 29.56% 1-Year Est. Return
RWI
Red Wave Investments Dillsburg, Pennsylvania $394M AUM 20.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
DIM
Delta Investment Management San Francisco, California $608M AUM 25.3% 1-Year Est. Return
AMH
Apollo Management Holdings New York $8.94B AUM 120.19% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $2.8B AUM 13.35% 1-Year Est. Return
EWM
Evermay Wealth Management Arlington, Virginia $971M AUM 17.81% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

Governors Lane's CLDI Position: Q3 2024 in Review

Governors Lane sold out of Calidi Biotherapeutics (CLDI) in Q3 2024, closing a stake of 25 shares — an estimated $9.47K sold.

Governors Lane first reported a position in CLDI in Q4 2021 and held it in 6 quarters. The position peaked at $9.94M in Q2 2022. 19 funds tracked by Wall St. Rank hold CLDI as of Q3 2024.

  • Governors Lane reported no remaining Calidi Biotherapeutics position as of Q3 2024 after selling out during the quarter.
  • Governors Lane sold 25 Calidi Biotherapeutics shares in Q3 2024, an estimated $9.47K.
  • Governors Lane first reported a position in Calidi Biotherapeutics in Q4 2021 and held it in 6 quarters.
  • Governors Lane's Calidi Biotherapeutics position peaked at $9.94M in Q2 2022.
  • 19 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q3 2024.

Based on Governors Lane's 13F filing for Q3 2024, filed 14 Nov 2024.